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Background: Berberine is known to improve glucose and lipid metabolism disorders, but it poorly absorbed into
the blood stream from the gut. Therefore, the exact underlying mechanism for berberine is still unknown. In this
study, we investigated the effect of berberine on glucose metabolism in diabetic rats and tested the hypothesis
that berberine acts directly in the terminal ileums.
Methods: Rats were divided into a control group, diabetic group (DM), low dose of berberine group (BerL) and
high dose of berberine group (BerH). Ileum samples were analyzed using a Roche NimbleGen mRNA array, qPCR
and immunohistochemistry.
Results: We found that 8 weeks of treatment with berberine significantly decreased fasting blood glucose levels.
An oral glucose tolerance test (OGTT) showed that blood glucose was significantly reduced in the BerL and BerH
groups before and at 30 min, 60 min and 120 min after oral glucose administration. Plasma postprandial glucagon-
like peptide-1 (GLP-1) levels were increased in the berberine-treated groups. The ileum from the BerH group had
2112 genes with significantly changed expression (780 increased, 1332 decreased). KEGG pathway analyses indicated
that all differentially expressed genes included 9 KEGG pathways. The top two pathways were the MAPK signaling
pathway and the GnRH signaling pathway. Q-RT-PCR and immunohistochemistry verified that glucagon-like peptide 1
receptor (Glp1r) and mitogen activated protein kinase 10 (Mapk10) were significantly up-regulated, in contrast,
gonadotropin releasing hormone receptor (Gnrhr) and gonadotropin-releasing hormone 1 (Gnrh1) were
down-regulated in the BerH group.
Conclusion: Our data suggest that berberine can improve blood glucose levels in diabetic rats. The mechanisms
involved may be in the MAPK and GnRh-Glp-1 pathways in the ileum.
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Diabetes is a disorder of the metabolism of carbohydrates,
lipids and proteins in which the body cannot produce insu-
lin or cannot use it to its full potential. Over 135 million
people are affected by diabetes worldwide [1]. Diabetes can
cause long-term complications such as retinopathy, neur-
opathy and nephropathy, and people with diabetes are at
higher risk of myocardial infarction, stroke and limb ampu-
tation. Diabetes therapy is centered upon the control of* Correspondence: xiaoxinhua@medmail.com.cn
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unless otherwise stated.blood glucose levels. Management of hyperglycemia with
few side effects remains a challenge to the medical system.
Rhuzima Coptidis was recorded as an anti-diabetes
medication approximately 1500 years ago in a book ti-
tled “Note of Elite Physicians” by Hongjing Tao. Berber-
ine is the major active component of Rhizoma coptidis,
and many studies have been published on the glucose
reducing mechanisms of berberine. Zhou et al. found
that berberine stimulated glucose transport through a
mechanism distinct from insulin in 3T3-L1 adipocyes [2].
Moreover, berberine could activate AMPK and induced gly-
colysis in L6, C2C12, and 3 T3-L1 cell lines [3]. Additio-
nally, berberine dose-dependently inhibited respiration inLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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complex I [4].
Berberine has beneficial properties in lipid and glucose
metabolism regulation and has been effectively used in
the treatment of diabetes, obesity and hypercholesterol-
emia. However, berberine has a low bioavailability [5],
which is attributed to its poor aqueous solubility and
dissolution.
Thus, we hypothesized that berberine can change gene
expression in the intestine directly to moderate lipid and
glucose metabolism. To understand the exact mecha-
nisms, we used a type 2 diabetes rat model to investigate
differential expression of genes in the intestine.
Methods
Animal modeling, groups, and treatment
Male Sprague–Dawley rats (280–320 g) were purchased
from the Institute of Laboratory Animal Science, Chin-
ese Academy of Medical Sciences and Peking Union
Medical College (Beijing, China, SCXK-2012- 0007). Ac-
cording to a previous study [6] diabetic rats were fed a
high-fat diet (40% of calories as fat) for 4 weeks and then
administered with a single dose of streptozotocin (STZ,
50 mg/kg, tail vein) formulated in 0.1 mmol/l citrate
buffer, pH 4.5 (Sigma-Aldrich, Germany). One week
after the STZ injection, the random blood glucose levels
of the diabetic rats were measured to confirm hyper-
glycemia. Random blood glucose measurements above
16.7 mmol/l were used to define rats as diabetic. Diabetic
rats were fed a high-fat diet throughout the experiment.
Diabetic rats with a similar degree of hyperglycemia were
randomly divided into three groups: vehicle, low dose
berberine (BerL), and high dose berberine (BerH)
groups (n = 8, in each group). The typical human daily
dose of berberine is 1200 mg/60 kg body weight.
According to the formula: drat = dhuman X 0.71/0.11 [7],
the corresponding dose of berberine for rats is 129.09 mg/
kg per day, so we selected 120 mg/kg and 240 mg/kg per
day as low and high dosages, respectively. The control
(n = 8) and vehicle group received 0.5% saline, whereas
the BerL and BerH groups were given berberine at
120 mg/kg and 240 mg/kg in 0.5% saline, respectively.
The drug was administered once daily for 8 weeks using
a gastric gavage. All animals were housed in an envi-
ronmentally controlled room at 25°C in a 12 h light:
12 h darkness cycle and given free access to food and
water throughout the experimental period. Fasting ani-
mals were allowed free access to water. After 6 weeks of
treatment, an oral glucose tolerance test (OGTT) was per-
formed. After 8 weeks of treatment, blood samples were
taken from the rats after anesthesia. The rats were then
sacrificed. Some terminal ileum sample was collected
to perform the microarray and quantitative real-time
PCR (qRT-PCR) experiments. Some terminal ileumsample was fixed in 10% neutralized formalin for im-
munohistochemical staining. All procedures involving
animals were approved by the animal care and use
committee of the Peking Union Medical College Hospital
(Beijing, China, MC-07-6004) and were conducted in
compliance with the Guide of the Care and Use of Labora-
tory Animals (NIH publication No. 86-23, revised 1996).
All surgeries were performed under sodium pentobar-
bital anesthesia, and all efforts were made to minimize
suffering.
Measurement of body weight and fasting blood
glucose levels
Body weight was monitored every 2 weeks. The 6-h fast-
ing blood glucose (FBG) level was measured monthly
using the enzyme end-point method (Roche, Germany)
with blood from a tail bleed.
Oral glucose tolerance test (OGTT)
After the rats fasted for 6 h, 2.2 g/kg of glucose was orally
administered. Then, blood samples were collected from
tail veins at 0 min (prior to glucose load), 30 min, 60 min,
and 120 min (after glucose load) for the glucose assay.
The area under the curve (AUC) was calculated for
blood glucose during the OGTT using the following
equation: AUC = 0.5 × (BG0 + BG30)/2 + 0.5 × (BG30 +
BG60)/2 + 1 × (BG60 + BG120)/2, where BG is blood
glucose.
Serum biochemistry analysis
At week 6, after the rats fasted for 6 h, the animals were
euthanized. Rats received 2.2 g/kg of glucose by gavage,
then the abdominal cavity was opened and a canula was
inserted in the portal vein. Before the glucose load, some
blood samples were taken and then centrifuged at
1000 g for 10 min. Serum was stored in aliquots at -80°C
for an assay of serum fasting insulin. At 15 min following
the glucose load, portal blood samples were collected in
EDTA tubes containing dipeptidyle peptidase IV inhibitor
(10 μL/mL blood sample, Millipore, MA, USA) via the
portal vein. Plasma samples were obtained and stored
at -80°C for assessment of glucagon-like peptide-1 (GLP-1).
Serum insulin and plasma active GLP-1 (i.e., GLP-1 [7-36
amide] and GLP-1 [7-37]) was measured with an ELISA
(Millipore, USA). HOMA-IR = FBG (mmol/L) × FINS
(μU/mL)/22.5.
RNA preparation and whole-genome gene expression
profiling array experiments
The terminal ileum was taken from the BerH group and
DM group (n = 3, in each group) to perform the micro-
array experiments. We selected the Rat 12 × 135 K Gene
Expression Array which was manufactured by Roche
NimbleGen (Germany). This array includes approximately
Table 1 Olgonucleotide sequences for Q-PCR
Gene
symbol






Glp1r: glucagon-like peptide 1 receptor; Gnrh1: gonadotropin releasing
hormone 1; Gnrhr: gonadotropin releasing hormone receptor; Mapk10:
mitogen activated protein kinase 10.
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RNA was harvested using TRIzol (Invitrogen, CA, USA)
and an RNeasy kit (Qiagen, Valencia, CA, USA) accord-
ing to the manufacturer’s instructions. Total RNA from
each sample was quantified by the NanoDrop ND-1000
and RNA integrity was assessed by standard denaturing
agarose gel electrophoresis. The total RNA of each sample
was labeled using a NimbleGen One-Color DNA labeling
kit and hybridized in a NimbleGen Hybridization System.
After hybridization and washing, the processed slides were
scanned with an Axon GenePix 4000B microarray scanner
(Molecular Devices Corporation, USA). The microarray
experiment was independently repeated in triplicate.
Gene array data analysis
The data files were imported into Agilent GeneSpring
Software (Agilent, version 11.0, USA) for analysis. The
gene expression level in the BerH group was normalized
to that in the DM group. Differentially expressed genes
were identified through Fold Change and t-test P-value
screening.
To assign biological meaning to the group of genes
with changed expression, the subset of genes that met
the above criteria was analyzed with the Gene Ontology
(GO) classification system, using Database for Annotation,
Visualization, and integrated Discovery (DAVID) software
(http:david.abcc.ncifcrf.gov/) [8] as well as the Kyoto
Encyclopedia of Genes and Genomes (KEGG). All
thresholds in our analyses were set to 0.001. Over-
representation of genes with altered expression within
specific GO categories was determined using the one-
tailed Fisher exact probability modified by the addition
of a jack-knifing procedure, which penalizes the signifi-
cance of categories with very few (eg. one or two) genes
and favors more robust categories with larger numbers
of genes [9].
Quantitative real time PCR analysis
For validation of the microarray results, quantitative real
time PCR (Q-RT-PCR) analyses were performed using
SYBR Green. Each Q-RT-PCR assay was repeated using
three biological replicates and each analysis consisted of
three technical replicates. Before PCR, each total RNA
was processed with RNase-free DNase (Qiagen, Valencia,
CA, USA). RNA was reverse transcribed by Superscript
II (Invitrogen, CA, USA). The primers were designed
using Applied Biosystems (Foster City, CA, USA) Primer
Express™ design software. Primers were purchased from
Applied Biosystems (Table 1). The reaction production
could be accurately measured in the exponential phase
of amplification by the ABI prism 7700 Sequence Detec-
tion System, with the following cycling conditions: an
initial denaturation at 48°C for 30 min, 95°C for 15 min,
40 cycles of 95°C for 15 sec, 55°C for 1 min, and a finalunlimited 4°C hold. The sequences of the primers used
are listed in Table 1. The signal of the housekeeping gene
glyceraldehyde-3-phosphate dehydrogenase (Gapdh) was
used for normalization. Relative quantification of the
mRNA between BerL, BerH and DM rats was calculated
with the comparative Ct method [10].Immunohistochemical straining
Ileum samples from the BerH and DM groups (n = 6 in
each group) were fixed in 10% neutral buffered formalin,
cast in paraffin, sliced into 4-μm sections and placed
onto microscope slides. After the removal of the paraffin
by xylene and dehydration by graded alcohol, the slides
were immersed into distilled water. Ileum sections were
then transferred into a 10 mmol/L citrate buffer solution
(pH 6.0) and heated at 80°C for 5 min for antigen re-
trieval. After washing, 3.0% peroxide was applied for
20 min to block the activity of endogenous peroxidase.
To avoid nonspecific staining, the sections were incu-
bated in blocking solution (5% BSA, Sigma, Germany)
for 1 h at room temperature, followed by treatment with
rabbit polyclonal anti-GLP1R antibody (1:100, Abcam
lnc., UK), or rabbit polyclonal anti-MAPK10 antibody
(1:100, Abcam Inc., UK), where indicated, overnight at
4°C. Negative control sections were stained under identi-
cal conditions by substituting the primary antibody with
equivalent concentrations of normal rabbit IgG. After
washing with phosphate-buffered saline, the slides were
incubated with a labeled streptavidin biotin reagent, fol-
lowing the manufacturer’s instructions. Immunoreactive
products were visualized with the DAB reaction. Sec-
tions were counterstained with hematoxylin for 15 sec.
Brownish yellow granular or linear deposits were inter-
preted as positive areas. Three observers who were
blinded to the clinical information evaluated the immu-
nohistochemical staining scores independently. Staining
intensity was graded semi-quantitatively using the H-
SCORE [11], which was calculated using the following
equation: H-SCORE = ∑Pi (i + 1), where i is the intensity
of staining with a value of 1, 2 or 3 (mild, moderate, or
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cells stained with different intensity, varying from 0% to
100%. The results are expressed as the mean ± SE. Dif-
ferences between the groups were statistically analyzed
with a one-way analysis of variance (ANOVA). A P value
of < 0.05 was considered significant.
Statistical analysis
All results are expressed as the mean ± standard devi-
ation (SD). Statistical analyses were performed with ana-
lysis of variance followed by Student’s t-test. P < 0.05 was
considered statistically significant. Analysis was done
with SPSS 11.0 (SPSS, Inc., Chicago, IL, USA).
Results
Berberine showed no effect on body weight of DM rats
The mean body weight of diabetic rats was significantly
decreased compared to the control rats at week 2 (P <
0.05), week 4 (P < 0.01), week 6 (P < 0.01) and week 8
(P < 0.01). No significant differences were noted be-
tween the DM group and berberine-treated groups
(Figure 1A).
Berberine decreased fasting blood glucose of DM rats
The fasting blood glucose (FBG) levels of DM rats and
the BerL group and BerH group were significantly higher
than those of control rats at week 0 (P < 0.01), week 2
(P < 0.01), week 4 (P < 0.01), week 6 (P < 0.01) and weekFigure 1 The body weight (A) and fasting blood glucose (B)
before and after berberine treatment in the rats (n = 8, in each
group). Data represent mean ± S. D. (n = 8). *P < 0.05, **P < 0.01
versus the control group; #P < 0.05 versus DM group.8 (P < 0.01). FBG in the BerL group and BerH group de-
creased significantly at week 2 (P < 0.05), week 4 (P <
0.05), week 6 (P < 0.05) and week 8 (P < 0.05) compared
to the DM group (Figure 1B).Berberine moderated the glucose tolerance of DM rats
The blood glucose levels of the DM, BerL and BerH
groups were higher than those of the control group
before (0 min, P < 0.01) and at 30 min (P < 0.01),
60 min (P < 0.01) and 120 min (P < 0.01) after oral glu-
cose administration. Blood glucose levels of the BerL
and BerH groups significantly decreased before (0 min,
P < 0.05) and after oral glucose administration (P <
0.05 all above, Figure 2A). The AUC of OGTT for the
DM, BerL and BerH groups increased compared to
the control group (P < 0.05). The AUC for the BerL
and BerH groups reduced compared with the DM
group (P < 0.05, Figure 2B).Berberine reduced FINS and HOMA-IR in DM rats
FINS and HOMA-IR levels of the DM rats were signifi-
cantly elevated (P < 0.01) after 8 weeks of treatment and
berberine significantly suppressed FINS (P < 0.05) and
HOMA-IR (P < 0.01, Figure 3A and B).Berberine increased GLP-1 in DM rats
Plasma postprandial GLP-1 levels in the BerH group
were increased to the DM group (Figure 3C).Figure 2 The effect of berberine on oral glucose tolerance test
blood glucose (A) and AUC (B) in rats (n = 8, in each group).
Data represent mean ± S. D. (n = 8). **P < 0.01 versus the control
group; #P < 0.05 versus DM group.
Figure 3 The effect of berberine on serum fasting insulin (A), HOMA-IR (B) and plasma postprandial GLP-1 (C) in rats (n = 8, in each
group). Data represent mean ± S. D. (n = 8). **P < 0.01 versus the control group; # P < 0.05, ##P < 0.01 versus DM group.
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There were 2,112 differentially expressed genes identified in
the terminal ileum between the BerH group and DM group.
Of those, 780 genes (36.9%) were up-regulated and 1,332
genes (63.1%) were down-regulated in the BerH group.
The aforementioned DAVID annotation tool was used
for identification of GO and putative KEGG pathways.
DAVID analysis of all the differentially expressed genesyielded 55 GO categorues (FDR<0.001, Table 2). The
genes were mapped to 9 pathways (FDR < 0.001, Table 3).
Two of the most common types of enriched pathways
were the MAPK signaling pathway (FDR = 3.26E-19) and
the GnRH signaling pathway (FDR = 1.01E-13). In the
MAPK signaling pathway, in particular, 266 genes were
represented on the gene array, of which 95 genes were
differentially expressed.
Table 2 Gene ontology groups with significant over-representation among genes with significantly changed expression
in the BerH (FDR < 0.001)
GO classification Go term GO ID Count Fold enrichment FDR
Biological process Intracellular signaling cascade GO:0007242 60 7.195 1.61E-18
Phosphate metabolic process GO:0006796 55 7.186 1.06E-17
Phosphorus metabolic process GO:0006793 55 7.169 1.20E-17
Protein kinase cascade GO:0007243 34 14.126 7.10E-16
Regulation of phosphorylation GO:0042325 37 10.287 1.03E-15
Regulation of phosphate metabolic process GO:0019220 37 9.890 4.11E-15
Regulation of phosphorus metabolic process GO:0051174 37 9.890 4.11E-15
Protein amino acid phosphorylation GO:0006468 42 7.539 2.09E-14
Regulation of kinase activity GO:0043549 32 12.455 2.41E-14
Regulation of transferase activity GO:0051338 32 11.872 1.06E-13
Response to organic substance GO:0010033 48 5.738 2.16E-13
Regulation of protein kinase activity GO:0045859 30 12.280 1.81E-12
Phosphorylation GO:0016310 42 6.516 5.62E-12
MAPKKK cascade GO:0000165 24 18.618 9.75E-12
Positive regulation of kinase activity GO:0033674 26 14.494 5.94E-11
Positive regulation of transferase activity GO:0051347 26 13.866 1.81E-10
Response to endogenous stimulus GO:0009719 37 7.163 2.64E-10
Positive regulation of molecular function GO:0044093 34 7.439 6.39E-09
Positive regulation of protein kinase activity GO:0045860 24 13.939 8.79E-09
Positive regulation of catalytic activity GO:0043085 32 7.995 1.47E-08
Response to hormone stimulus GO:0009725 33 7.178 8.01E-08
Regulation of apoptosis GO:0042981 32 5.243 2.47E-06
Regulation of programmed cell death GO:0043067 32 5.174 3.54E-06
Regulation of cell death GO:0010941 32 5.152 4.01E-06
Activation of protein kinase A activity GO:0034199 9 66.561 3.21E-05
Enzyme linked receptor protein signaling pathway GO:0007167 21 8.320 7.94E-05
Regulation of MAP kinase activity GO:0043405 15 14.469 2.47E-04
Cellular response to hormone stimulus GO:0032870 16 12.588 2.76E-04
Negative regulation of catalytic activity GO:0043086 19 9.007 3.78E-04
cAMP biosynthetic process GO:0006171 8 73.957 4.80E-04
Activation of protein kinase activity GO:0032147 14 15.687 6.06E-04
Cellular constituent Cytosol GO:0005829 46 4.618 4.08E-17
Cell fraction GO:0000267 32 3.714 9.48E-08
Nucleoplasm GO:0005654 25 4.037 5.43E-06
Insoluble fraction GO:0005626 25 3.716 2.73E-05
Soluble fraction GO:0005625 16 6.026 5.40E-05
Organelle lumen GO:0043233 31 2.849 1.12E-04
Plasma membrane GO:0005886 45 2.108 1.93E-04
Membrane-enclosed lumen GO:0031974 31 2.772 2.06E-04
Nuclear lumen GO:0031981 26 3.148 3.24E-04
Intracellular organelle lumen GO:0070013 28 2.668 0.002417965
Molecular function Protein kinase activity GO:0004672 38 7.617 4.54E-12
Purine ribonucleotide binding GO:0032555 53 3.841 1.29E-11
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Table 2 Gene ontology groups with significant over-representation among genes with significantly changed expression
in the BerH (FDR < 0.001) (Continued)
Ribonucleotide binding GO:0032553 53 3.839 1.33E-11
Protein serine/threonine kinase activity GO:0004674 30 8.615 2.66E-11
Purine nucleotide binding GO:0017076 53 3.660 1.11E-10
ATP binding GO:0005524 46 4.169 6.83E-10
Adenyl ribonucleotide binding GO:0032559 46 4.087 1.47E-09
Adenyl nucleotide binding GO:0030554 46 3.856 1.44E-08
Purine nucleoside binding GO:0001883 46 3.789 2.78E-08
Nucleoside binding GO:0001882 46 3.759 5.66E-08
Nucleotide binding GO:0000166 53 3.059 3.25E-07
MAP kinase activity GO:0004707 9 59.748 7.78E-06
Adenylate cyclase activity GO:0004016 8 82.079 1.34E-05
Phosphoprotein phosphatase activity GO:0004721 15 13.329 5.76E-05
Kinase binding GO:0019900 16 10.031 5.56E-04
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To confirm that protein expression in the GLP1R and
MAPK pathways was altered in the ileum of DM rats
treated with berberine, immunohistochemistry analyses
for GLP1R and MAPK10 were performed on ileum tis-
sues. In the BerH group, there was a statistically signifi-
cant increase in the immunoreactivities of GLP1R and
MAPK10 (Figure 4).Q-RT-PCR experiment
We used Q-RT-PCR assays to verify some of the micro-
array results. Four genes [Glucagon-like peptide 1 receptor
(Glp1r), gonadotropin-releasing hormone 1 (Gnrh1),
gonadotropin releasing hormone receptor (Gnrhr) and
mitogen activated protein kinase 10 (Mapk10)] were se-
lected for verification, because of their central positions
in the MAPK signaling pathway and GnRH signaling
pathway. The expression ratios of these four genes, as
determined through microarrays and Q-RT-PCR, are
shown in Table 4. Glp1r and Mapk10 were up-regulated;
while Gnrhr and Gnrh1 were down-regulated in both of
the BerL group and BerH group. Strong agreement be-
tween the microarray and Q-RT-PCR results was observed
for both genes, indicating the reliability of our microarray
assays.Discussion
In this study, we found that the administration of berberine
to diabetic rats significantly reduced fasting blood glucose,
moderated glucose tolerance and reduced serum insulin.
These results suggest that berberine can moderate glucose
metabolism and ameliorate oral glucose tolerance andinsulin sensitivity. These results are similar to the results
of other studies [12-16].
Moreover, we found that berberine increased plasma
GLP-1 after an oral glucose load. GLP-1 is a gut derived
hormone secreted from intestinal L cells in response to
glucose [17]. GLP-1 exerts important effects on the
regulation of glucose metabolism, stimulating glucose-
dependent insulin secretion and promoting β cell prolif-
eration [18]. At the same time, GLP-1 inhibits glucagon
release, gastric emptying and food intake [19]. Berberine
may increase GLP-1 (7-36) amide secretion in STZ-
induced diabetic rats [20], even in normal SD rats [21].
Recently, Shan et al. found that berberine could increase
GLP-2 in type 2 diabetic rats [22].
We found that berberine could increase the expression
of Glp1r in gene array experiments and Q-PCR experi-
ments. Camilleri et al. found that GLP-1 can suppress
gastrointestinal movement [23]. Furthermore, Feng et al.
found that berberine could inhibit myoelectrical activity
and gastrointestinal transit in rodents [21]. Therefore,
berberine can increase plasma GLP-1 levels and Glp-1r
expression to suppress gastrointestinal movement, mo-
derate insulin secretion, and therefore moderate glucose
metabolism.
In KEGG analysis, we found that the significant path-
way in the berberine-treated group was the MAPK sig-
naling pathway. Q-RT-PCR verified this result. TNF-α is
interconnected with MAPK pathways. Waetzig et al.
found that SB203580, a p38 inhibitor, significantly reduced
mucosa secretion of TNF-α [24]. Hollenbach et al. found
that SB203580 can reduce the mRNA levels of proinflam-
matory cytokines (i.e., TNF-α, IL-2 and IL-18) in the gut
of BALB/c mice [25].
Table 3 KEGG pathway (FDR < 0.001, Fold enrichment > 2.0)
KEGG_ID Term Count Total number







95 266 17.985 3.26E-19 RGD1565395, HRAS, PDGFA, TGFB3, NFKB1, FGF12, NFKB2,
DAXX, TGFB1, TGFB2, AKT1, CDC42, FOS, CASP3, MOS, RRAS,
PRKACA, PRKACB, FAS, MAP2K7, AKT3, AKT2, MAP2K5, EGFR,
PRKCA, RELA, PTPRR, TP53, FLNC, ECSIT, FLNB, PRKCB, MAPK1,
MAP4K4, RASGRF1, JUN, MAPK3, PDGFRA, HSPB1, MAPK9,
PDGFRB, MAPK8, MAP3K14, GADD45A, FGFR2, FGFR1, TRAF2,
GRB2, MRAS, MAPKAPK5, MKNK2, DUSP10, ELK1, HSPA1A,
HSPA1B, MAPKAPK2, HSPA1L, TNFRSF1A, HSPA2, ELK4, SOS1,
SOS2, DUSP16, RAC1, PPP3CB, PPP3CC, PPP3CA, CHP, HSPA8,
PTPN7, MAP2K1, MAP2K2, PTPN5, MAP2K3, NLK, MAP2K4,
TAOK3, NR4A1, RAF1, MAPK10, DUSP5, NRAS, DUSP4, DUSP3,
ATF4, DUSP2, DUSP1, MAPK14, NTRK2, IKBKG, MAPK8IP3,
DUSP9, IKBKB, CRK, DUSP7, DUSP6
rno04912 GnRH signaling
pathway
42 94 22.501 1.01E-13 ADCY3, ADCY4, ADCY1, HRAS, ADCY2, ADCY7, GRB2, ADCY5,
GNA11, ADCY6, ELK1, GNRHR, MMP2, CDC42, PTK2B, SOS1,
SOS2, PRKACA, PRKACB, MAP2K7, EGFR, PRKCA, GNRH1,
MAP2K1, MAP2K2, MAP2K3, MAP2K4, RAF1, MAPK10, MMP14,
PRKCD, PRKCB, MAPK1, NRAS, ATF4, GNAQ, ADCY9, JUN,
MAPK14, MAPK3, MAPK9, MAPK8
rno04540 Gap junction 29 81 18.030 9.06E-11 ADCY3, ADCY4, ADCY1, HRAS, ADCY2, ADCY7, PDGFA, GRB2,
ADCY5, GNA11, ADCY6, SOS1, SOS2, PRKACA, PRKACB,
MAP2K5, PRKCA, EGFR, MAP2K1, MAP2K2, RAF1, PRKCB, NRAS,
MAPK1, ADCY9, GNAQ, MAPK3, PDGFRA, PDGFRB
rno04722 Neurotrophin signaling
pathway
31 126 12.390 2.14E-09 HRAS, GRB2, NFKB1, MAPKAPK2, AKT1, CDC42, SOS1, RAC1,
SOS2, MAP2K7, AKT3, AKT2, MAP2K5, MAP2K1, MAP2K2, RELA,
TP53, RAF1, MAPK10, PRKCD, NRAS, MAPK1, ATF4, JUN,
MAPK14, MAPK3, NTRK2, MAPK9, MAPK8, IKBKB, CRK
rno05200 Pathways in cancer 43 317 6.831 4.57E-08 FGFR2, TRAF2, FGFR1, HRAS, PDGFA, GRB2, TGFB3, NFKB1,
FGF12, NFKB2, MMP2, TGFB1, TGFB2, AKT1, CDC42, FOS,
CASP3, SOS1, SOS2, RAC1, FAS, AKT3, AKT2, EGFR, PRKCA,
MAP2K1, MAP2K2, RELA, TP53, RAF1, MAPK10, PRKCB, MAPK1,
NRAS, JUN, IKBKG, MAPK3, PDGFRA, PDGFRB, MAPK9, MAPK8,
IKBKB, CRK
rno04662 B cell receptor
signaling pathway
25 75 16.786 9.81E-07 HRAS, GRB2, NFKB1, AKT1, FOS, SOS1, RAC1, SOS2, PPP3CB,
PPP3CC, CHP, PPP3CA, AKT3, AKT2, MAP2K1, MAP2K2, RELA,
RAF1, PRKCB, NRAS, MAPK1, JUN, MAPK3, IKBKG, IKBKB
rno04660 T cell receptor
signaling pathway
28 109 12.936 2.43E-06 HRAS, GRB2, NFKB1, AKT1, CDC42, FOS, SOS1, SOS2, PPP3CB,
PPP3CC, PPP3CA, CHP, MAP2K7, AKT3, AKT2, MAP2K1, MAP2K2,




32 171 9.424 2.04E-05 ADCY3, ADCY4, ADCY1, HRAS, ADCY2, ADCY7, GRB2, ADCY5,
ADCY6, NFKB1, AKT1, CDC42, PTK2B, SOS1, SOS2, RAC1,
PRKACA, PRKACB, AKT3, AKT2, MAP2K1, RELA, RAF1, PRKCD,
PRKCB, NRAS, MAPK1, ADCY9, IKBKG, MAPK3, IKBKB, CRK
rno05215 Prostate cancer 25 90 13.988 1.32E-04 FGFR2, FGFR1, HRAS, PDGFA, GRB2, NFKB1, AKT1, SOS1, SOS2,
AKT3, AKT2, EGFR, MAP2K1, MAP2K2, RELA, TP53, RAF1, NRAS,
MAPK1, ATF4, IKBKG, MAPK3, PDGFRA, PDGFRB, IKBKB
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http://www.biomedcentral.com/1472-6882/14/188The GnRH signaling pathway was the second path-
way in KEGG analysis. Q-PCR experiments also
showed Gnrh1 and Gnrhr was reduced in the BerH
group. Gonadotropin-releasing hormone (GnRH) and
its receptor were expressed in the rat gastrointestinal
system, pancreas and submaxillary glands, and its
receptor had the same mRNA sequence with that of
the hypothalamus, which demonstrated that GnRH
was a brain-gut peptide [26,27]. Intestinal GnRH hada regulatory role on the endocrine and exocrine func-
tions of the digestive system. GnRH and its receptor
were also expressed in glucagon-immunoreactive cells
of the rat ileum. GnRH analogs had a regulatory role
on intestinal glucagon-like immunoreactivity [28]. A
focused literature review showed GnRH agonists
could increase the weight and fat mass and insulin
resistance syndrome in men. These results indicate
that GnRH may increase the risk of diabetes mellitus
Figure 4 The iluem immunohistochemistry for GLP1R and MAPK10 expression (original magnification × 200) and semiquantitative
assessments. A-B Immunostaining for GLP1R. C-D immunostaining for MAPK10. Iluem were harvested form DM (A, C) and berH group (B, D).
(E) Semiquatitatve scores of GLP1R and MAPK10. Data represent mean ± SD (n = 6). #P < 0.05 versus DM group.
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http://www.biomedcentral.com/1472-6882/14/188[29]. In premenopausal women with symptomatic uter-
ine leiomyomas, GnRH agonists also increased insulin
levels and HOMA scores [30]. Moreover, Antide, a
GnRH receptor antagonist, administration prevented an
increased incidence of diabetes in a castrated male non-
obese mouse model of autoimmune diabetes (NOD)
mice [31]. In addition, GnRH modulates the expression
of insulin in the NOD mouse independently of gonadal
steroids. These results demonstrated that GnRH could
inhibit insulin secretion by islet cells in vitro experi-
ments [32]. Thus, berberine may moderate blood glu-
cose and insulin secretion through decreasing activity of










Glp1r 3.862 4.6 ± 0.3 0.027
Gnrh1 −4.615 −3.7 ± 0.2 0.038
Gnrhr −3.715 −3.1 ± 0.4 0.014
Mapk10 6.362 5.9 ± 0.3 0.031
Glp1r: glucagon-like peptide 1 receptor; Gnrh1: gonadotropin-releasing hormone 1;
protein kinase 10.
Each Q-RT-PCR assay was repeated using three biological replicates and each analyConclusion
In conclusion, our studies provide evidence that berberine
reduces blood glucose and insulin in diabetic rats.
The mechanism may be within the MAPK pathway
and GnRH-GLP-1 pathway in the ileum. These results
provide molecular information for further investiga-
tion of the mechanisms by which berberine moderates
glucose metabolism. Furthermore, these results could
be important in devising mechanism-based and targeted
therapeutic strategies for diabetes. More experiments
should been performed in the future to confirm these
results (such as studying gastrointestinal movement and









4.231 4.3 ± 0.2 0.026
−3.758 −3.5 ± 0.3 0.025
−3.271 −2.9 ± 0.4 0.039
5.837 6.2 ± 0.5 0.015
Gnrhr: gonadotropin releasing hormone receptor; Mapk10: mitogen activated
sis consisted of three technical replicates.
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